{"slideshow_credits": null, "snippet": "The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments.", "abstract": "Novartis agrees to buy multiple sclerosis drug ofatumumab, sold under the name Arzerra, from GlaxoSmithKline for up to $1 billion.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Amie", "role": "reported", "lastname": "TSANG", "rank": 1, "organization": ""}, {"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 2, "organization": ""}], "original": "By AMIE TSANG and ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/08/22/business/dealbook/novartis-buys-glaxo-drug-for-1-billion.html", "lead_paragraph": "The experimental drug ofatumumab would bolster the Swiss pharmaceutical company\u2019s portfolio of multiple sclerosis treatments.", "headline": {"main": "Novartis to Buy Multiple Sclerosis Drug From Glaxo", "print_headline": "Business Briefing; Novartis Buys Glaxo Multiple Sclerosis Drug"}, "_id": "55d6e3cc38f0d81d6b2effea", "word_count": "528", "multimedia": [], "pub_date": "2015-08-22T00:00:00Z", "source": "The New York Times", "news_desk": "Dealbook", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "GlaxoSmithKline PLC", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Novartis AG", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Multiple Sclerosis", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}